Synchronous or metachronous colorectal liver metastases (CLMs), although being the expression of systemic disease, allow a curative approach for about 2535% of patients. Patients presenting with CLMs should receive a multimodal management in order to increase the number of patients undergoing R0 surgery and to decrease the rate of recurrence. Postoperative and/or pre-operative systemic chemotherapy shows beneficial impact regarding progression-free and overall survival, without increasing postoperative complication rates. Concerning the complex definition of resectability and the number of patients with 'borderline' resectable CLMs, pre-operative chemotherapy plays an important role in both the improvement of prognosis and 'conversion' to resectability. Duration of chemotherapy in the perioperative setting should not exceed 6 months. Current data do not recommend the use of locally applied chemotherapy using hepatic artery infusion after resection of CLMs. Liver surgery has made several advances extending resectability to a larger group of patients and decreasing local hepatic recurrence. Moreover, locally ablative procedures such as radiofrequency and selective internal radiation therapy have joined the armamentarium in the case of positive resection margins or unresectable disease. Future research will help in defining treatment regimens and approaches in this setting.
Introduction
Colorectal cancer (CRC) is one of the most common cancers worldwide with a cumulative lifetime risk of approximately 5% leading to over 500,000 deaths each year [Boyle and Ferlay, 2005] . About 25% of patients with CRC present with metastatic disease at time of diagnosis. In addition, up to 35% of patients will develop colorectal liver metastases (CLMs) during their course of disease after curative resection of the primary tumor, of whom 2030% present with liver metastases only [Weiss et al. 1986 ]. It has been shown that surgical resection of CLMs is a potentially curative treatment, with reported 5-year survival rates ranging from 20% to 40% [Choti et al. 2002; Weber et al. 2000 ]. Further follow up after resection of CLMs has demonstrated that long-term survival rates depend on prognostic clinical factors, but still offer a chance for cure in select patients with 'poor' prognostic factors [Tomlinson et al. 2007; Fong et al. 1999; Scheele et al. 1995] . However, the majority of patients will relapse after liver resection. Patterns of recurrences are intrahepatic manifestations in two thirds of cases, extrahepatic disease in about 50%, and about 25% relapse in both regions [de Jong et al. 2009 ]. This raises the question about whether or not new multimodal approaches, incorporating peri-operative chemotherapy, new surgical techniques, and locally ablative procedures may contribute to the reduction of recurrence and prolongation of overall survival (OS).
Selection of patients for a potential curative approach
The selection of patients for hepatic surgery is a controversial issue. Several scoring systems try to predict survival after resection of CLMs, e.g. the presence of positive portal lymph nodes, extrahepatic metastases, four or more hepatic metastases or primary tumor stage Duke's C [Hughes et al. 1986 ]. The scoring system used by Fong and colleagues incorporates five risk factors: node-positive primary; disease-free interval <12 months; >1 lesion; size >5 cm; and carcinoembyonic antigen (CEA) >200 ng/ml. Patients with five risk factors had a 5-year survival rate (5-ySR) of 14% with a median of 22 months compared with a 5-ySR of 44% and a median of 51 months in the case of one risk factor [Fong et al. 1999] . Recently, the prognostic value of this score was revalidated and found to be suitable as a decision-making tool in daily practice [Merkel et al. 2009 ].
Whereas the estimation of survival is broadly accepted, criteria for resectability are far from being well and uniformly defined, and several manuscripts have addressed this issue recently without consensus Poston et al. 2008; Yamaguchi et al. 2008; Nagashima et al. 2006; Van Cutsem et al. 2006 ]. For example, the EORTC 40983 trial included patients with up to four potentially resectable liver metastases and no evidence of extrahepatic disease [Nordlinger et al. 2008] .
Recent clinical trials used the definition to include patients depending on resectability only determined by a surgeon with hepatic surgery expertise (refer to www.ClinicalTrials.gov). Generally, a postresection remnant liver of less than 30%, unfavorable location of metastases, comorbidities excluding major surgery, aggressive tumor biology, and/or the presence of extrahepatic disease are regarded as limitations for liver surgery. However, although the number (more than four) and size (more than 5 cm) of CLMs have an impact on prognosis [Yamaguchi et al. 2008] , patients could still be considered resectable. A 'European Expert Panel' recently stated that the resection should have the potential to be complete and macroscopically curative. However, the definition of clear irresectability seems to be more important regarding the choice of treatment strategy if pre-operative chemotherapy will be administered to all patients with CLMs that are either initially resectable or potentially resectable after remission ].
The role of peri-operative treatment in resectable CLMs is still a matter of debate. Further questions are sequence (pre-operative versus postoperative treatment), mode (systemic versus local) and intensity (monotherapy versus combination). Although postoperative therapy after resection of CLM has become an accepted standard of care in many parts of the world, data on the benefit are limited. There are only a few randomized trials comparing pre-operative and/or postoperative intravenous chemotherapy or hepatic artery infusion (HAI) with or without intravenous chemotherapy with surgery alone. Moreover, in adjuvant systemic chemotherapy none of the conducted clinical trials achieved the recruitment goal, leading to solely premature data.
Peri-operative treatment for resectable CLMs
The EORTC 40983 trial accrued 364 patients to be randomized to two treatment arms: surgery alone or chemotherapy with 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX4 regimen), administered 3 months pre-operatively and postoperatively [Nordlinger et al. 2008] . Patients had to be technically resectable (assessed by CT scan) with a maximum of four CLMs and no prior treatment with oxaliplatin. Although patients' characteristics were favorable, with more than 50% bearing only a single CLM and about 80% with up to two, respectively, and surgery was performed in 'high-quality' institutions, the reported 3-year disease-free survival (DFS) rates were relatively poor, but significantly increased from 33.2% (surgery alone) to 42.4% in the group of patients (n ¼ 171) receiving the planned chemotherapy and resection of CLMs (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.550.97). However, in the intent-to-treat analyses, the difference was not statistically significant due to ineligibility of 6% of patients (HR 0.79, 95% CI 0.621.02); see Table 1 . No unusual toxicities occurred in the chemotherapy arm, and about 80% of patients completed the preoperative part. After resection, 76% of patients received postoperative treatment with the majority (52%; n ¼ 80) completing all six cycles. Those numbers strongly remindus of the situation in resectable gastric cancer with around 40% of patients completing the postoperative chemotherapy in a peri-operative treatment strategy further emphasizing the role of the neoadjuvant part [Cunningham et al. 2006 ].
During pre-operative chemotherapy, reported main grade 3/4 toxicities (according to National Cancer Institute Common Toxicity Criteria [NCI CTC] version 2.0) were nausea and vomiting in 4%, diarrhea in 8%, stomatitis in 7%, sensory neuropathy in 2%, and neutropenia in 18% (febrile 2%) of patients. Reversible complications were significantly higher (25% versus 16%, p ¼ 0.04) in the chemotherapy group. In particular, intra-abdominal infections, biliary fistulas with an output of more than 100 ml per day for more than 10 days, and hepatic failure with a bilirubin-elevation grade 3/4 for more than 3 days occurred more often in the peri-operative group. There was no impact on postoperative death rate (1% in both arms). During postoperative chemotherapy, as expected, toxicities included grade 3 sensory neuropathy (10%) and other neurological toxicities (12%), due to the cumulative dose of oxaliplatin.
According to those data, peri-operative chemotherapy is regarded as a standard for patients with resectable CLM in many parts of Europe. However, OS data are still pending, but expected for later this year. Furthermore, the results of the EORTC 40983 trial consequently led to the EORTC 40051 'BOS' study with FOLFOX and cetuximab±bevacizumab, which was stopped after the results of the CAIRO2 study [Tol et al. 2009 ]. The three-arm BOS-2 trial will now compare FOLFOX alone versus FOLFOX combined with bevacizumab versus FOLFOXpanitumumab in the peri-operative setting. Results of a recently published single-arm phase II trial using capecitabine, oxaliplatin, and bevacizumab as peri-operative treatment in resectable CLMs displayed 52 R0-resections of CLMs in 56 patients with, notably, 11 resections of CLMs and the primary tumor. Three patients had progressive disease and one was diagnosed with outspread extrahepatic disease during laparotomy. Survival data or adherence to postoperative therapy were not reported [Gruenberger et al. 2008] .
Postoperative systemic treatment
Two randomized phase III trials have compared adjuvant systemic chemotherapy with 5-FU/folinic acid (FA) after resection of CLM to surgery alone, but both were closed prematurely due to slow accrual. By the time of closure, a small but statistically significant improvement in recurrence-free survival (RFS) could be shown in the FFCD (Fédération Francophone de Cancérologie Digestive) trial, with a 5-year RFS rate of 26.7% versus 33.5% (p ¼ 0.028), favoring the group with adjuvant treatment [Portier et al. 2006 ]. Although the 5-year overall survival rate (OSR) increased from 41.1% to 51.1%, this difference was not significant (p ¼ 0.13). The ENG (EORTC/NCI-CTG/GIVIO) trial, still not fully published, showed a nonsignificant trend towards a prolongation of RFS (median 39 versus 20 months; p ¼ 0.35) and an increase in OS (median 53 versus 43 months; p ¼ 0.39) [Langer et al. 2002] . The combined analysis of both trials (n ¼ 278 patients) showed a nonsignificant prolongation of median DFS from 18.8 to 27.9 months (p ¼ 0.058) and OS from 47.3 to 62.2 months (p ¼ 0.095) [Mitry et al. 2008 ]. Both trials were using a (noncontemporary) 5-FU bolus regimen.
Recently, the intensification of the postoperative treatment by 5-FU plus irinotecan in a prematurely stopped, randomized phase III trial revealed no additional benefit over 5-FU alone in terms of OS (3-year survival rate of 73% versus 72%) [Ychou et al. 2009 ]. Regarding median DFS, there was a nonsignificant increase of 3 months (21.6 versus 24.7 months, HR 0.90, 95% CI 0.67À1.2, p ¼ 0.44). The gain in DFS is possibly too small to be detected with only 150 patients per group. However, the lack of a clear benefit also corresponds well to the data of adjuvant treatment with FOLFIRI (5-FU/FA/ irinotecan) in stage III CRC [Van Cutsem et al. 2009b ]. Results of a retrospective analysis of a European and North-American registry further support the use of postoperative 5-FU-based chemotherapy revealing a significant prolongation of median OS (47 versus 36 months) translating into an increase in the 5-year OSR of 31 versus 37% (p ¼ 0.007) [Parks et al. 2007 ]. It is questionable whether further insight regarding adjuvant chemotherapy will be available, as two current postoperative trials (ADHOC, NSABP C-09) were closed due to insufficient accrual. However, some planned trials such as the US NSABP C11, the Australian ATTACHE, and the German AIO/CAO trial are planned to evaluate peri-operative versus postoperative treatment on the basis of a FOLFOX plus bevacizumab regimen.
Postoperative local treatment/hepatic artery infusion
Several trials were comparing postoperative HAI combined with or without systemic treatment to surgery alone with diverging results. In the German trial by Lorenz and colleagues, adjuvant HAI with 5-FU (1000 mg/m 2 per day for 5 days as continuous 24-hour infusion) modulated by FA (200 mg/m 2 per day) for 6 months was administered after hepatic resection. The trial was stopped after an interim analysis of 226 patients revealed a detrimental effect on OS for the adjuvant group and a similar time-to-progression of around 14 months in both groups [Lorenz et al. 1998 ]. However, postoperative HAI of floxuridine (FUDR) in combination with intravenous continuous 5-FU significantly improved the 4-year RFS rate from 25% with surgery alone to 46% with the combined treatment [Kemeny et al. 2002] . The initial dose of FUDR was 0.10.2 mg/kg per day for 14 days to a maximum of four cycles. The 5-FU dose was 200 mg/m 2 per day as continuous 14-day infusion for four cycles, followed by 300 mg/m 2 per day as continuous 14-day infusion for additional eight cycles. Possible explanations for these conflicting data are the use of different drugs for HAI (5-FU/FA versus FUDR), different schedules (5 days versus 14 days) and the addition of systemic 5-FU in the (positive) trial by Kemeny and colleagues.
The contribution of systemic treatment to HAI has not yet been evaluated. HAI with FUDR and dexamethasone plus systemic chemotherapy with 5-FU±LV compared to systemic chemotherapy alone showed a significant increase in 2-year OSR (86% versus 72%, p ¼ 0.03), becoming smaller and nonsignificant in an updated survival analysis after 10 years (41% versus 27%, p ¼ 0.07) in a randomized trial with 156 patients [Kemeny et al. 1999 [Kemeny et al. , 2005 . A Japanese trial investigating a similar question with systemic 5-FU±HAI with 5-FU revealed a trend towards increased DFS and OS. Owing to the small sample size (19 patients) this difference did not reach statistical significance [Tono et al. 2000 ].
Randomized trials evaluating adjuvant HAI compared with hepatic resection alone are summarized in Table 2 [Rudroff et al. 1999; Lygidakis et al. 1995; Wagman et al. 1990 ]. The systematic review by Nelson and Freels of 592 patients revealed a nonsignificant survival advantage in favor of the control (non-HAI) group of 8.9% (HR 1.089, 95% CI 0.8871.334). Regarding these results, application of HAI may not be recommended as a standard of care [Nelson and Freels, 2006 ].
Surgical resection of metastases
Resection of CLM has developed into a highly sophisticated field in operative surgery, extending resectability to an increasing number of patients and decreasing local hepatic recurrence. However, the criteria for resectability are not uniformly defined yet and are usually related to the subjective decision of the treating physicians. In 'borderline' resectable CLM, a consensus between different surgeons could be difficult, as shown in a recent German investigation of the CELIM trial [Folprecht et al. 2010 ]. Herein, computed tomography (CT) and magnetic resonance imaging (MRI) scans of 'borderline' CLM patients were presented to a board of experienced liver surgeons in order to assess the likelihood of resectability. The investigators were blinded for treatment course (before or after treatment with a highly active regimen), patients' clinical outcome and the assessment of the other investigators. Herein, a concordance of decisions in 64.5% of cases and a critical disagreement (resectable versus nonresectable) in 6.8% were reported. These data emphasize the problem in defining resectability in patients with CLM.
Recent technical advances in surgery are a targeted approach with intra-operative ultrasound, the reduction of hemorrhage, by either lowering the central venous pressure or using radiofrequency or water jet transection devices, tailored operative approaches (anatomic hepatic resection, staged hepatic resection or ex-vivo resection of metastases in the posterior segments), upfront improvement of operability by portal vein ligation or embolization and hypertrophy of the remaining segments, and the reduction of local recurrence by cryofrequency or radiofrequency ablation techniques of positive margins [Covey et al. 2008; Khatri et al. 2005] .
Recently published data revealed that a safety margin of 0.5 mm is sufficient, without limiting the prognosis of patients Jonas et al. 2007; Pawlik et al. 2005 ]. If surgery for CLM is performed by experienced surgeons the microscopic infiltration (R1) of the resection margins does not seem to have an impact on prognosis, with a 10-ySR of 37% for R1 compared with 43% for R0 resections [de Haas et al. 2008b] .
Moreover, patients with CLM and with extrahepatic disease can also be regarded as candidates for cure. For example, resection of lung metastases were also reported with a 5-ySR of 45% in a highly selected group [Figueras et al. 2007; Inoue et al. 2004] . Several series revealed 5-ySR of around 30% for the resection of both liver and lung metastases counted after the last organ resection [Miller et al. 2007; Kobayashi et al. 1999; Murata et al. 1998 ]. Recently, a large series of 186 patients with CLM and extrahepatic disease (lung 51%, lymph node metastases 26% and peritoneal metastases 12%) was reported. For patients with CLM and lung metastases (n ¼ 88), OSR at 5 years (counted after first pulmonary resection) was 37%, although one third of patients had bilateral pulmonary disease. In the case of involvement of other sites, e.g. lymph node metastases which were reported in 8%, 5-ySR was much lower [de Haas et al. 2008a] . Recently, data from a French group have shown that even resection of localized peritoneal carcinomatosis may also result in longterm survival. This indicates a further field of multimodal treatment, with systemic chemotherapy, surgery and intraperitoneal chemotherapy [Elias et al. 2010 ].
Controversies about the choice of an 'optimal' pre-operative treatment for patients with CLM The group of patients with 'borderline' resectable metastases warrants a highly active treatment regimen, aiming to 'convert' unresectable CLMs into resectability. Toward this aim, tumor shrinkage is an important issue. Regarding the reported RECIST response rates in first-line trials of metastatic CRC with manifestations not confined to the liver, combination chemotherapy with a monoclonal epidermal growth factor receptortargeting antibody (in k-ras wild-type patients) or a three-drug chemotherapy combination regimen seem to be a reasonable choice: the response rates are higher compared with those reported for combination chemotherapy with bevacizumab Van Cutsem et al. 2009a; Saltz et al. 2008; Falcone et al. 2007; Hurwitz et al. 2004 ]. However, these trials have included all patients with metastatic CRC, and the benefit confined to CLM and 'conversion rates' therefore cannot be assessed. The recently reported CELIM trial included 110 patients with 'potentially resectable' CLM as the only manifestation. RECIST response rates of 70% resulted from treatment with oxaliplatin or irinotecan-based chemotherapy in combination with cetuximab in the k-ras wild-type population. Using the methodology as described above for the determination of resectability, a conversion rate of 28% towards resectability was reported, leading to R0 resection in 34% of patients.
Although tumor shrinkage is important for technical resectability, and RECIST response rates are likely to correlate well with the percentage of resected or 'converted' patients, it has to be kept in mind that prognosis of patients may (also) be determined by the effect of treatment on tumor tissue. Interestingly, a good correlation of pathohistologic response in the tumor specimen with OS were reported from a cohort of patients with resection of CLM after pre-operative chemotherapy [Blazer et al. 2008] . For bevacizumab-containing regimens, higher rates of pathologic response have been reported in a retrospective series of patients after pretreatment with FOLFOX plus bevacizumab compared with FOLFOX alone [Zorzi and Kishi, 2009] . Another issue of defining the 'optimal regimen' is that response to treatment may be displayed in the change of radiographic morphologic pattern rather than in tumor shrinkage only [Chun et al. 2009 ]. The issue of complete radiological response has to be kept in mind during administration of neoadjuvant treatment. In a retrospective analysis of 66 CLMs with complete radiological response (CT scans), 46 could not be detected intra-operatively. Furthermore, resection of 15 metastases revealed viable tumor cells in 12 of them (80%). The remaining 31 metastases were left in situ with 23 locally recurring within 1 year [Benoist et al. 2006 ]. Therefore, patients should be closely monitored during pre-operative chemotherapy and resected before complete remission [Nordlinger et al. 2007 ].
One of the major drawbacks in neoadjuvant treatment is unresectability in the case of progression during chemotherapy. In the EORTC 40983 trial, 12 (7%) patients experienced progressive disease during pre-operative chemotherapy leading to unresectability in eight patients, half of them presenting with new lesions [Nordlinger et al. 2008 ]. However, a switch to unresectability also reveals an aggressive tumor biology, and likely predicts a worse outcome even in the case of resection. Therefore, it is unclear whether progressing patients should still undergo surgery.
Chemotherapy can result in severe damage of the liver tissue. Whereas oxaliplatin-based combinations are associated with increased risk of vascular lesions, irinotecan-containing regimens have been associated with increased risk of steatohepatitis, mainly in obese patients with a relevantly increased body mass index [Benoist and Nordlinger, 2009; Vauthey et al. 2006 ]. The clinical impact of chemotherapy-associated histological changes seems to favor oxaliplatin in the neoadjuvant setting. Increased risk of peri-operative bleeding, postoperative complication rate and poorer functional reserve was found to be associated with vascular lesions. Although the influence on morbidity is still controversial, mortality was not affected [Nakano et al. 2008; Vauthey et al. 2006 ]. In the EORTC 40983 trial, the peri-operative treatment resulted in a similar postoperative death rate as compared with surgery alone, with a significantly higher rate of reversible postoperative complications (p ¼ 0.04). Higher risk of complications was similarly reported for irinotecan-associated steatohepatitis [Kooby et al. 2003 ]. However, Vauthey and colleagues revealed an increased 90-day mortality (14.7% versus 1.6% OR 10.5) in patients with steatohepatitis compared to those without [Vauthey et al. 2006 ]. Therefore, selection and duration of pre-operative therapy should be reviewed cautiously. The addition of anti-VEGF (vascular endothelial growth factor) antibodies to neoadjuvant oxaliplatin-based treatment could reduce the rate of sinusoidal dilation [Ribero et al. 2007 ] without limiting the ability of liver regeneration [Gruenberger et al. 2008 ].
In conclusion, the optimal duration of peri-operative chemotherapy is still controversial. Chemotherapy was administered either 6 months postoperatively or 3 months pre-operatively and postoperatively in European trials. In the combined modality trial published by Kemeny and colleagues, treatment lasted for 12 months, consisting of 4 months combined local and systemic, followed by 8 months of systemic chemotherapy [Kemeny et al. 2002] . However, the current, European and American Guidelines (NCCN version 1.2010) recommend a treatment duration of 6 months for perioperative therapy.
Conclusion
The prognosis of patients with CLMs depends on the access of the patient to an optimal multimodal treatment. Recent advances in liver surgery have enabled more potentially curative resections. Systemic peri-operative chemotherapy, administered pre-operatively and/or postoperatively, has been shown to decrease recurrence and to improve patients' prognosis. Although the data are somewhat controversial, several national guidelines have given a recommendation for the use of any peri-operative chemotherapy in the cases of resectable liver metastases. In detail, the controversy is whether this should be applied preoperatively and/or postoperatively. For example, a 'should be considered' recommendation for the use of postoperative 5-FU treatment after R0 resection of CLM and a 'should be considered in a few clinically indicated situations' for the use of peri-operative FOLFOX was recommended by the German guidelines [Schmiegel et al. 2008] , whereas the expert panel on behalf of the European Colorectal Metastases Treatment Group recommends the use of pre-operative chemotherapy in the case of both resectable and unresectable liver metastases ].
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